It’s hard to believe we’re coming to the close of 2021—a year filled with hopes for whatever a return to “normal” might be thanks to amazing feats of science to deliver effective vaccines and the realities of new coronavirus variants and the inequities of vaccine distribution. This is a reflective time of year for many people—our team included. We are counting the reasons to be grateful in the midst of challenges, and how we can share what we have with others.
Here’s what we know we are grateful for: together, our generosity and impact go further. That’s why we’re shining an end-of-year spotlight on some of the Gates Foundation’s and Gates Philanthropy Partners’ amazing grantee partners. Think of it as one-stop-shopping for ways to give well. With these partners, you can have confidence that your investment will make a real difference in real time.
Use the links below to give directly to these trusted grantees, or visit the Gates Philanthropy Partners website here to give with us through one of our funds.
EMPOWERMENT & OPPORTUNITY
Investing in women transforms communities
Women’s collectives have long demonstrated how communities of women can tackle poverty. In many places, these communities of women are both bearing the brunt of the pandemic’s impacts and also leading the response. SEWA Bharat is a vibrant network of informal women worker collectives across India, supporting women’s groups with emergency pandemic relief, protection of livelihoods, and laying the foundation for an equal recovery for all.
To donate directly to SEWA Bharat’s important work, visit here for donating in India. Visit GiveIndia to give from the United States.
Reaching the last mile to end the pandemic
Controlling COVID-19 means getting vaccines, information, and health care to everyone, everywhere—even rural and remote areas. VillageReach provides supply chain and tech-enabled strategies to solve the immense challenges of last mile health care delivery. Currently, VillageReach supports the pandemic response of Ministries of Health, including actively assisting with COVID-19 vaccine readiness and rollout in Côte d’Ivoire, Democratic Republic of Congo, Liberia, Malawi, Mozambique, and specific counties in Washington State.
Disease Elimination & Eradication: Donor collaboration makes big dent in NTDs
The END Fund is an innovative funding collaborative working to end the five most common neglected tropical diseases (NTDs). These five parasitic and bacterial infections impact the health and well-being of over 1.7 billion people globally—robbing many of educational and economic opportunities and limiting their chances to escape the cycle of poverty. The END Fund employs an innovative, cost-effective, systems-based approach to get NTD treatments to those who need them.
U.S. Education: Breaking down barriers to college success
Higher education has historically been an engine of social mobility and economic growth in the United States, but Black, Latino, Indigenous students and students from low-income backgrounds face enormous systemic barriers to earning their degrees. OneGoal is demonstrably improving college enrollment and college persistence by addressing these barriers at scale, bridging the critical transition between high school and college with individualized, tech-enabled support.
Global Health Innovation: Partnering with governments to save lives
Big issues require a big response. Cardiovascular disease is the world’s biggest killer of people in their prime—but it doesn’t have to be. Resolve to Save Lives, led by former U.S. CDC director Tom Frieden, fuses technology and public health to help governments tackle the world’s number one killer through evidence-based policy changes and public education to reduce salt intake, eliminate trans fats from diets, and raise awareness regarding hypertension.
We are ever thankful for these dedicated grantees and their amazing work. And we are thankful for YOU and everyone who puts the “partner” in Gates Philanthropy Partners.
May the joy of giving fill all of our proverbial cups during this season of giving.